Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Accenture
Cipla
QuintilesIMS
Medtronic
McKinsey

Generated: July 23, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,080,526

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,080,526 protect, and when does it expire?

Patent 8,080,526 protects LINZESS and is included in one NDA.

This patent has eighty-three patent family members in twenty-four countries.

Summary for Patent: 8,080,526
Title:Methods and compositions for the treatment of gastrointestinal disorders
Abstract: The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
Inventor(s): Currie; Mark (Sterling, MA), Mahajan-Miklos; Shalina (Stanford, CA), Milne; G. Todd (Brookline, MA), Norman; Thea (Cambridge, MA)
Assignee: Ironwood Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:12/754,138
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,080,526
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 8,080,526
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 8,080,526

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan Sales Llc LINZESS linaclotide CAPSULE;ORAL 202811-003 Jan 25, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Allergan Sales Llc LINZESS linaclotide CAPSULE;ORAL 202811-001 Aug 30, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Allergan Sales Llc LINZESS linaclotide CAPSULE;ORAL 202811-002 Aug 30, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Covington
Federal Trade Commission
Johnson and Johnson
Argus Health
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.